A New Chapter in Neoadjuvant Therapy for High-risk Prostate Cancer?

被引：1
|
作者：
Krafft, Ulrich [1 ,2 ]
Hadaschik, Boris A. [1 ,2 ]
Lueckerath, Katharina [2 ,3 ]
Herrmann, Ken [2 ,3 ]
机构：
[1] Univ Duisburg Essen, Univ Hosp Essen, Dept Urol, Essen, Germany
[2] Univ Duisburg Essen, Univ Hosp Essen, West German Canc Ctr, Essen, Germany
[3] Univ Duisburg Essen, Univ Hosp Essen, Dept Nucl Med, Essen, Germany
来源：
EUROPEAN UROLOGY | 2024年 / 85卷 / 03期
关键词：
D O I：
10.1016/j.eururo.2023.09.022
中图分类号：
R5 [内科学]; R69 [泌尿科学（泌尿生殖系疾病）];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页数：2
相关论文
共 50 条
  • [41] Neoadjuvant docetaxel and estramustine chemotherapy in high-risk/locally advanced prostate cancer
    Hussain, M
    Smith, DC
    El-Rayes, BF
    Du, W
    Vaishampayan, U
    Fontana, J
    Sakr, W
    Wood, D
    [J]. UROLOGY, 2003, 61 (04) : 774 - 780
  • [42] ARNEO: neoadjuvant degarelix + apalutamide before surgery for high-risk prostate cancer
    Fenner A.
    [J]. Nature Reviews Urology, 2022, 19 (11) : 634 - 634
  • [43] Phase II study of neoadjuvant 'supercastration' in men with high-risk prostate cancer
    Corcoran, N.
    Howard, N.
    Bugeja, P.
    Kerger, M.
    Moon, D.
    Clarke, D.
    Grummet, J.
    Hovens, C.
    Costello, T.
    Pedersen, J.
    Ryan, A.
    Ruljancich, P.
    Parente, P.
    [J]. BJU INTERNATIONAL, 2014, 113 : 18 - 18
  • [44] Neoadjuvant endocrine therapy with palbociclib in patients with high-risk breast cancer
    Lonning, P. E.
    Clausen, C.
    Blix, E. S.
    Lundgren, S.
    Vagstad, G.
    Espelid, H.
    Gilje, B.
    Janssen, E. A.
    Geisler, J.
    Aas, T.
    Aase, H.
    Knappskog, S.
    Eikesdal, H. P.
    [J]. ANNALS OF ONCOLOGY, 2019, 30 : 59 - +
  • [45] Molecular features of exceptional response to neoadjuvant anti-androgen therapy in high-risk localized prostate cancer
    Tewari, Alok K.
    Cheung, Alexander T. M.
    Crowdis, Jett
    Conway, Jake R.
    Camp, Sabrina Y.
    Wankowicz, Stephanie A.
    Livitz, Dimitri G.
    Park, Jihye
    Lis, Rosina T.
    Bosma-Moody, Alice
    He, Meng Xiao
    AlDubayan, Saud H.
    Zhang, Zhenwei
    McKay, Rana R.
    Leshchiner, Ignaty
    Brown, Myles
    Balk, Steven P.
    Getz, Gad
    Taplin, Mary-Ellen
    Van Allen, Eliezer M.
    [J]. CELL REPORTS, 2021, 36 (10):
  • [46] Radical prostatectomy with long neoadjuvant hormonal therapy can be effective for high-risk localized prostate cancer patients
    Kato, M.
    Tsuzuki, T.
    Hattori, R.
    Gotoh, M.
    [J]. EUROPEAN UROLOGY SUPPLEMENTS, 2012, 11 (01) : E350 - E350
  • [47] Bortezomib as brief neoadjuvant therapy for localized high-risk prostate cancer (PCa) followed by radical prostatectomy (RP)
    Sonpavde, G.
    Frolov, A.
    Macdonell, V.
    Hayes, T. G.
    Mims, M. P.
    Ayala, G. E.
    Wheeler, T. M.
    Thompson, T. C.
    Ittman, M. M.
    Kadmon, D.
    [J]. JOURNAL OF CLINICAL ONCOLOGY, 2009, 27 (15)
  • [48] Predictive factors associated with differential pathologic response to neoadjuvant chemohormonal therapy in high-risk localized prostate cancer
    Fan, Junjie
    Liang, Hua
    Gu, Yanan
    Jiang, Zhangdong
    Jiang, Fan
    Wang, Yingchun
    He, Dalin
    Wu, Kaijie
    [J]. UROLOGIC ONCOLOGY-SEMINARS AND ORIGINAL INVESTIGATIONS, 2023, 41 (08) : 354e1 - 354e9
  • [49] Radiotherapy and hormone therapy in patients with high-risk prostate cancer
    [J]. Nature Clinical Practice Urology, 2008, 5 (1): : 4 - 4
  • [50] Controversies in the therapy of high-risk prostate cancer. Radiotherapy
    Boehmer, D.
    [J]. ONKOLOGE, 2015, 21 (09): : 805 - +
12345